Apellis Pharmaceuticals, Inc.
APLS
$17.97
$0.080.45%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -56.41% | 156.92% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -56.41% | 156.92% | |||
| Cost of Revenue | 12.12% | 14.98% | |||
| Gross Profit | -73.77% | 273.89% | |||
| SG&A Expenses | 3.10% | 8.80% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.65% | 11.15% | |||
| Operating Income | -122.91% | 770.50% | |||
| Income Before Tax | -127.11% | 618.93% | |||
| Income Tax Expenses | -48.01% | 29.18% | |||
| Earnings from Continuing Operations | -127.33% | 611.77% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -127.33% | 611.77% | |||
| EBIT | -122.91% | 770.50% | |||
| EBITDA | -122.73% | 780.64% | |||
| EPS Basic | -127.28% | 610.10% | |||
| Normalized Basic EPS | -127.05% | 617.37% | |||
| EPS Diluted | -129.26% | 599.25% | |||
| Normalized Diluted EPS | -127.83% | 602.85% | |||
| Average Basic Shares Outstanding | 0.19% | 0.32% | |||
| Average Diluted Shares Outstanding | -2.62% | 3.21% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||